ReviewJournal of orthopaedic surgery and research2025
TGF-β signaling in heterotopic ossification: the pathogenesis and the target for its treatment.
Review in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Heterotopic Ossification (HO) is a complex and multifactorial pathological process characterized by abnormal bone production in areas outside the skeletal system (e.g., inside muscles, periarticular joints, ligaments, and tendons). This pathology is mainly classified as traumatic and hereditary, and it involves several signaling pathways, such as Wnt/β-catenin, BMP, hedgehog signaling, and transforming growth factor (TGF)-β family. TGF-β plays a key role in the development of HO as an important regulator of cartilage formation and differentiation, and endochondral ossification is a common manifestation of HO. Studies have shown that TGF-β can play an initiating and facilitating role in various stages of HO development, and that ectopic bone formation can be effectively reduced by systemic injection of TGF-β-neutralizing antibodies. This review summarizes the role of TGF-β signaling in the pathogenesis of HO and discusses potential preventive and therapeutic means to target TGF-β signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.